In patients with hematological malignancy (HM) developing acute respiratory failure (ARF) bronchoalveolar lavage (BAL) is considered as a major diagnostic tool. However, the benefit/risk ratio of this invasive procedure is probably lower in the subset of patients with acute myeloid leukemia (AML). The study was to analyze the yield of BAL performed in HM patients (n ¼ 175) with AML or lymphoid malignancies (LM) admitted in intensive care unit (ICU) for ARF and pulmonary infiltrates. BAL was performed in 121 patients (53/73 AML patients (73%) and 68/102 LM patients (67%)) without a definite diagnosis at admission or contraindication for fiberoptic bronchoscopy. Life-threatening complications were noticed in 12/121 patients (10%). The overall diagnostic yield of BAL was 47% (25/53) in AML patients and 50% (34/68) in LM patients. A microorganism was recovered from BAL in 23% (12/53) of AML patients and 41% (28/68) of LM patients (Po0.005). BAL results induced significant therapeutic changes in 17% (9/53) of AML patients vs 35% (24/68) of LM patients (P ¼ 0.039). This study underlines the rather low diagnostic yield of BAL for infectious diagnosis and the low rate of therapeutic changes induced by its results in AML patients with ARF admitted in ICU.
Introduction
In patients with acute leukemia, pulmonary complications (PCs) are frequent and represent a major cause of admission in intensive care unit (ICU). [1] [2] [3] PC are related to a large spectrum of infectious and noninfectious etiologies [4] [5] [6] [7] and, in case of acute respiratory failure (ARF), early identification of the cause of PC is associated with a better outcome. 8 Fiberoptic bronchoscopy with bronchoalveolar lavage (FOB-BAL) is usually considered as the cornerstone of diagnostic procedures in immunocompromised patients with pulmonary infiltrates. 6, 9 The rate of FOB-BAL-related complications is usually acceptable in patients with hematological malignancies (HM) without ARF. 7, 10 However, life-threatening complications such as worsening of previous hypoxemia or severe bleeding have been described and may precipitate ARF and the need for endotracheal intubation and invasive mechanical ventilation (MV). Some studies focusing on patients with acute leukemia suggested a lower diagnostic yield of FOB-BAL than what has been reported in patients with lymphoid malignancies (LM). 11, 12 These studies are still scarce and included only limited numbers of patients, making it difficult to draw any firm conclusion. However, these data lead to question the benefit/risk ratio of FOB-BAL in patients with acute myeloid leukemia (AML), in which high mortality rates (450%) have been reported when MV is required. 11, 13, 14 To confirm our hypothesis that FOB-BAL was probably nonuseful in AML with ARF, as compared to patients with LM, we performed a prospective study to determine the yield and therapeutic impact of FOB-BAL in AML and LM patients with pulmonary infiltrates and ARF requiring intensive care unit admission.
Patients and methods

Study design
All consecutive patients with HM admitted for a PC in the ICU of a university teaching hospital between 1993 and 2002 were included. ICU admission was decided if at least one of the following signs of ARF was present: need for MV (invasive or noninvasive), PaO 2 /FIO 2 ratioo250 mm Hg or a need for more than 6 l min of nasal oxygen supply to achieve an oxygen saturation above 92% and a respiratory rate 425 per min in spontaneously breathing patients. Patients were dichotomized in two categories: those with AML and those with LM including non-Hodgkin's lymphoma, Hodgkin's lymphoma, chronic lymphoid leukemia and multiple myeloma.
Definition and diagnosis of pulmonary complications
All patients underwent at least two sets of blood culture tests, cytobacteriological analysis of urine, a serum test for Aspergillus antigen (Platellia Bio-Rad; Marne la Coquette, France), urine testing for Legionella pneumophila antigen (available from 1999), sputum analysis if sputum could be obtained, a chest X-ray and an echocardiography. A spiral computerized tomography (CT) scan was performed when no pulmonary infiltrate was identified on chest X-ray and/or when pulmonary embolism was suspected. When pulmonary infiltrates were present, a CT scan was also considered. FOB-guided BAL was routinely considered when these noninvasive investigations did not provide a firm etiological diagnosis and when pulmonary infiltrates were detected.
BAL was not performed if (1) the patient refused or (2) if one of the following contraindications was present: major hypoxemia (PaO 2 /FiO 2 o100 mm Hg) despite invasive or noninvasive MV with 100% FIO 2 and PEEP, or uncontrolled hemodynamic failure or (3) when clinicians considered it was not worthy.
BAL consisted of infusion of three 50 ml aliquots of sterile 0.9% saline solution and aspiration. The aspect of the BAL fluid (BALF) was noted. BALF smears were stained for a differential cell count and direct examination to identify usual and opportunistic pathogens (mycobacteria, viruses, fungi and parasites). BALF aliquots were cultured. Complications of FOB-BAL were recorded: reaction to anesthesia, pneumothorax, bleeding or need for invasive MV within 6 h after the procedure.
According to published predefined criteria, 3 a multidisciplinary team (including a hematologist, a respiratory care physician and an infectious disease specialist) classified PC into three main categories: (1) infectious origin (bacterial, fungal, viral or yeast pneumonia) (2) noninfectious origin and (3) undetermined origin. The same multidisciplinary team evaluated the diagnostic yield of FOB-BAL and the therapeutic impact of its results by blindly reviewing medical, radiological, microbiological data and prescription charts of each patient.
FOB-BAL was considered as having a clinical impact when a significant therapeutic change was performed according to its findings. 15 These changes included introducing a new antiinfectious drug (when an infection was documented by FOB-BAL) or starting a specific noninfectious treatment such as chemotherapy for specific tumoral pulmonary disease and steroids for drug-induced pneumonia. Platelet and blood cells transfusions, diuretics to avoid fluid overflow were not considered as significant therapeutic changes as they are part of usual treatment care in HM patients with PC and ARF.
Antimicrobial treatments
In hematological wards as in ICU, all neutropenic patients with fever received broad-spectrum antibiotic regimens containing a b-lactam and often an aminoglycoside. Antifungal treatment (amphotericin B or voriconazole or caspofungin) was initiated in patients with persistent fever after 3-5 days of broad-spectrum empirical antibiotic therapy. Glycopeptides were used only when meticillin-resistant Staphylococcus infection or catheterrelated infection was suspected. However, in cases of septic shock with respiratory failure, the initial empiric anti-infectious treatment included the combination of b-lactam, quinolones, glycopeptide and an antifungal agent. Prophylactic cotrimoxazole was administrated to all transplanted patients requiring steroid treatment for graft-vs-host reaction and to CLL patients treated with fludarabine. Prophylactic antiviral treatment (aciclovir or valaciclovir) against Herpes virus family was prescribed systematically during the first year after transplantation and in CLL patients treated by fludarabine. Anti-CMV treatment was given when CMV pp65 antigen was detected.
Granulocyte colony-stimulating factor (G-CSF) was administrated to all neutropenic patients with lymphoid malignancies. In AML patients, G-CSF was administrated in case of neutropenia with a delayed neutrophil recovery.
Statistical analysis
Factors related to a positive BAL result were studied by univariate analysis using Student's t-test for continuous variables, the w 2 -test for categorical variables, and Fisher's exact test for small expected frequencies. Significant differences (Po0.05) observed on univariate analysis were evaluated by multivariate logistic regression analysis. The Statview software (version 5.0) was used for statistical analysis (SAS Institute Inc., CA, USA).
Results
Characteristics of the patients
Between 1993 and 2002, 175 patients with HM were admitted in ICU for ARF, including 73 AML patients and 102 LM patients (Table 1) . Mean age was 54 years (range: 17-86) and 58% were men. Most patients (45%) were admitted at the earliest phase of the HM, that is, during either the diagnostic phase or induction Table 1 Characteristics of the patients with HM admitted in ICU (AML vs LM) for ARF Investigations FOB-BAL was performed in 121/175 patients (69%) ( Figure 1 ). The reasons for not performing BAL in other cases (n ¼ 54) are listed in Table 2 and were dominated by a definite etiological diagnosis by the mean of noninvasive diagnostic procedures.
As shown in Table 3 , neutropenia was more frequent in AML than in LM patients in whom BAL was performed. No other difference between these subgroups could be identified. 
Complications of FOB-BAL
Diagnostic yield of FOB-BAL and noninvasive investigations
Altogether, an etiological diagnosis was found in 114 patients (65%) ( Table 3 and Figure 1 ). As mentioned above, noninvasive investigations provided the diagnosis before FOB-BAL was envisaged in 42 cases. Among the 133 remaining patients, FOB-BAL was performed in 121 and considered as positive in 59 (49%), with isolation of an infectious organism in 40 (33%) and identification of a noninfectious pneumonia in 19 (16%). Among patients with a positive result of FOB-BAL (n ¼ 59), the diagnosis was also provided by noninvasive investigations in 10 cases (17%). When BAL was performed and negative (n ¼ 62), the diagnosis was provided by noninvasive investigations in 13 cases (21%). Table 4 compares the characteristics of the patients with or without a microorganism isolated from FOB-BAL. Factors significantly associated with the isolation of a microorganism in BALF were the nature of the underlying disease (LM vs AML) and the previous use of steroids. In AML patients, the diagnostic yield of FOB-BAL for infectious pneumonia was significantly lower in case of ARF occurring during induction treatment (3/28) vs other periods (9/27), P ¼ 0.04, and in neutropenic patients (3/28) vs non-neutropenic patients (9/27), P ¼ 0.04.
There was no difference in the diagnostic yield of BAL according to the alveolar or interstitial pattern of the lung scan.
Bacterial infection were the most frequent etiologies found in AML patients but the most frequent microorganism AML n = 73 LM n = 102
HM with ARF n = 175
. Infectious diagnosis: n = 8 . Non-infectious diagnosis: n = 6 . Contra indication: n = 4 . Refusal: n=2
No FOB-BAL n = 34 (33%)
. Infectious diagnosis: n = 13 . Non-infectious diagnosis: n = 15 . Contra indication: n = 4 . Refusal n = 2
Positive FOB-BAL: n=25 (47%)
. Infectious: n=12 (23%) . Non-infectious: n=13 (24%)
Positive FOB-BAL: n=34 (50%)
. 
Therapeutic impact of FOB-BAL
For all patients in whom FOB-BAL was performed (n ¼ 121), a significant therapeutic change occurred according to FOB-BAL findings in 33 cases (27.2%). Therapeutic changes induced by FOB-BAL results were significantly less frequent in AML patients (17%) than in LM patients (35%) (AML: n ¼ 9/53; LM: n ¼ 24/68; P ¼ 0.039).
For AML patients, a significant therapeutic change related to the isolation of a microorganism from FOB-BAL was made in only eight cases (15%). Regarding noninfectious etiologies, FOB-BAL induced a significant therapeutic change in only one patient. For LM patients, a significant therapeutic change related to the isolation of a microorganism in FOB-BAL was made in 22 cases. Regarding noninfectious etiologies, FOB-BAL induced a significant therapeutic change in two patients.
Outcome
In-ICU mortality was 31% (54/175) and 38 % (46/121) for the patients in whom a FOB-BAL was performed (P ¼ 0.21). In-ICU mortality was 45% (18/40) in patients with a diagnostic FOB-BAL and 35%, (28/81) in those with a nondiagnostic FOB-BAL (NS, P ¼ 0.32, Fischer's exact test). After 3 months, overall mortality was 46% (81/175) and 50% (60/121) for the patients in whom FOB-BAL was performed (NS) and 53 and 47% in AML patients and LM patients (NS), respectively. At 3 months, mortality was 44% in patients with a diagnostic FOB-BAL and 51% in patients with a nondiagnostic FOB-BAL (NS) and not different in between AML and LM patients (18 vs 26%, NS). In-ICU mortality of patients with significant therapeutic changes induced by FOB-BAL was lower but not significantly different from that of patients without significant therapeutic changes induced by FOB-BAL (ICU mortality: 12 vs 28%, respectively, P ¼ 0.09).
Discussion
The main findings of this study are the following: (1) FOB-BAL diagnostic yield and therapeutic impact is limited in AML, especially in neutropenic patients and during induction treatment. (2) In contrast, FOB-BAL is helpful in patients with lymphoid malignancies. (3) The most frequent microorganisms Table 2 Characteristics of the patients in whom a FOB-BAL was performed found were bacteria in AML patients and P. jirovecii in patients with lymphoid malignancies.
Overall diagnostic yield of FOB-BAL
FOB-BAL is considered as a very useful tool in immunocompromised patients with pulmonary infiltrates. [4] [5] [6] [7] 16, 17 FOB-BAL has also been largely evaluated in studies including patients with hematological malignancies. In these patients, reported diagnostic yields range from 35 to 60%. 8, 9, 11, 12, 15, 17, [18] [19] [20] [21] [22] [23] [24] We found comparable results in our patients with lymphoid malignancies, with a diagnostic yield of 50%. The much lower diagnostic yield of FOB-BAL in our AML patients with ARF admitted in ICU raises several issues, dominated by the differences in studied populations between available reports. Indeed, most of the studies evaluating FOB-BAL in HM patients included patients with heterogeneous underlying disease (lymphoid malignancies, myeloid malignancies, allogenic bone marrow transplantation and autologous bone marrow transplantation) and various levels of neutropenia, and only a few studies concerned ICU patients. Therefore, the results of these studies may not apply to the subset of HM patients with AML admitted in ICU for ARF. This point is important to emphasize as chemotherapy and immunosuppressive drugs are different in patients with myeloid malignancies, patients with lymphoid malignancies or transplanted patients. For example, steroids are not included in the treatment of patients with myeloid malignancies, although they are widely used in patients with lymphoid malignancies. Interestingly, in our study, the two factors significantly associated with the diagnosis of infection by BAL were use of steroids and the underlying disease (lymphoid malignancies vs AML patients).
Yield of FOB-BAL for the diagnosis of infectious pulmonary complications
The overall diagnostic yield of FOB-BAL in our AML patients admitted in ICU was 47%. However, considering infectious pneumonia, we found a low diagnostic yield (23%) and a very low therapeutic impact (15%) of FOB-BAL in these patients. To the best of our knowledge, no study on this topic focused on AML patients, although two publications addressed this issue in limited numbers (n ¼ 23 and 20, respectively) of patients with acute leukemia (including both AML patients and patients with acute lymphoblastic leukemia). 11, 12 A low diagnostic yield and therapeutic impact of BAL was also found in these studies (21 and 15%, respectively). The low diagnostic yield of FOB-BAL for infectious pneumonia found in AML patients experiencing a PC might be related to several factors.
First, we observed a high incidence of pulmonary infiltrates related to noninfectious diseases in these patients. Noninfectious etiologies of pulmonary infiltrates include a large panel of pulmonary diseases such as pulmonary leukostasis, acute lysis pneumonitis, pulmonary edema related to hydration, transfusion-related acute lung injury and all-trans-retinoic acid-related syndrome. 3, 6, 16 These complications may present with a typical radioclinical pattern and may respond rapidly to a specific treatment without the need for FOB-BAL. 16 Such complications are infrequent in lymphoid malignancies and absent after complete remission. In contrast, during consolidation and in bone marrow-transplanted patients, we observed a higher incidence of infectious etiologies. This could explain the lower diagnostic infectious yield of FOB-BAL at diagnosis (14%) of AML and during induction treatment (7%) than during consolidation treatment (50%) and after BMT (71%).
Second, AML patients receiving high-dose chemotherapy were more frequently neutropenic and experienced more Table 4 Factors influencing FOB-BAL infectious yield in patients with hematological malignancies admitted in ICU for pulmonary complications prolonged neutropenia than patients with lymphoid malignancies. It is well known that the increased duration of neutropenia is associated with more infectious events, which justifies the early use of broad-spectrum antibiotics. 25 This may decrease the probability of subsequently finding bacteria with BAL. Accordingly, FOB-BAL yield was lower in our neutropenic than in nonneutropenic patients: 11 vs 36%. Conversely, no such difference was found in a large study by Cordonnier et al. 18 However, it should be noticed that this study was not performed in ICU patients, although the number of patients who did not receive antibiotics was higher than in our study.
Third, the prolonged neutropenia observed in AML patients leads to a higher incidence of pulmonary aspergillosis than in previous studies. 2, 3, 8, 26 FOB-BAL diagnostic yield regarding Aspergillus species is low and we might have underestimated some cases of invasive aspergillosis in our patients. Indeed, Saito et al. 12 compared the results obtained with BAL to autopsy results. None of the nine patients with a definite diagnosis of pulmonary aspergillosis at autopsy had a positive FOB-BAL. Sharma et al. 27 also recently reported great discrepancy between pre-mortem diagnosis and autopsy findings in blood and bone marrow transplant patients with PCs. Recent studies using CT Scans, Aspergillus antigen detection, PCR Aspergillus antigen tests in BALF have reported an increase in FOB-BAL diagnostic yield, but the use of these tests is not generalized nor fully evaluated yet. 24 Also antifungal therapy reduced the rate of invasive aspergillosis.
Patients with LM or allogenic bone marrow transplantation receive steroids containing regimens and are therefore also exposed to infections in relation with T-cells deficiency such as P. jirovecii and viral infections. 6 Indeed, we found that the most frequent microorganism in LM was P. jirovecii. In other studies with more transplanted patients, CMV was the most frequent agent involved in PC. 19, 23, 25 New microbiological tools such as PCR may improve the diagnostic yield of FOB-BAL for fungi, viruses and P. jirovecii but were not routinely available at the time of our study. 24, 16 These new diagnostic tools may also increase FOB-BAL yield as many BAL were suboptimal in terms of BALF recovery as our patients were severely hypoxemic.
FOB-BAL-related therapeutic changes
FOB-BAL induced therapeutic changes in only 17% of patients. Comparable results varying from 16 to 25% were observed in previous studies. 9, 18, 20 Other authors found much higher therapeutic impact for FOB-BAL. 8, 15 Several facts may explain these discrepancies. The first is the frequent use of empirical broad-spectrum antibiotics especially in neutropenic patients before performing FOB-BAL: in our study, only 9% of patients did not receive antibiotics before FOB-BAL. A second reason is the definition used to evaluate the therapeutic impact of FOB-BAL result. For example, the diagnosis of alveolar hemorrhage was not associated with any significant therapeutic change as, in all AML patients with severe PC, our transfusion policy is to try to maintain the platelet count above the threshold of 50g/l by the mean of regular transfusions. Removal of unnecessary antibiotics is important to both the individual patient and the hospital, to avoid selecting antibiotic-resistant organisms. However, we did not consider the withdrawal of some antimicrobial drugs as a significant therapeutic change in our patients as de-escalation, as recommended for example in ventilator associated pneumonia, is not the rule for neutropenic patients with hematological malignancies. In fact, de-escalation of antimicrobial therapy was performed in non-neutropenic patients but it was not the rule in many neutropenic patients. Even when de-escalation was performed, it was rather difficult to relate this therapeutic change only to FOB-BAL result.
FOB-BAL-related outcomes
The 10% rate of FOB-BAL-related severe complications observed in our study is low but non-negligible and in accordance with previous studies. [9] [10] [11] [12] 16 We have no way to state that the 12 severe complications following BAL were indeed causally linked to this procedure. This 10% risk (6.5% risk of intubation) in our study may also be considered as acceptable but much higher rates of intubation following FOB-BAL have been reported in hypoxemic patients. 28 This result may be related to several factors such as the frequent use of noninvasive ventilation, the adequate training of the physicians who were all respiratory care physicians, platelets transfusion immediately before FOB procedure and a very close continuous monitoring during and following FOB.
In our study, patients with a positive FOB-BAL did not undergo a significantly better outcome than patients with a nondiagnosis FOB-BAL. In contrast to our results, Azoulay et al. 8 found a better prognosis in patients with a definite diagnosis. Accordingly, a better outcome but not statistically significant was observed in our patients when FOB-BAL results lead to significant therapeutic changes (ICU mortality: 12 vs 28%, P ¼ 0.09). The relatively low number of patients with significant therapeutic changes may explain why statistical significance was not reached.
In conclusion, a rather low diagnostic yield and infrequent therapeutic changes related to FOB-BAL results were found in patients with AML admitted to ICU for severe respiratory complications as compared to patients with lymphoid malignancies.
Considering the potentially life-threatening complications of FOB-BAL in these patients with severe thrombocytopenia, hypoxemia and a noninvasive diagnosis strategy (CT scan, cardiac echography, Aspergillus antigen, blood cultures and other blood test such as PCR) must be discussed and evaluated in a prospective randomized controlled study especially during induction treatment.
